Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.210
+0.760 (22.03%)
At close: Aug 3, 2026, 4:00 PM EDT
4.300
+0.090 (2.14%)
After-hours: Aug 3, 2026, 7:31 PM EDT
Camp4 Therapeutics Revenue
Camp4 Therapeutics had revenue of $1.29M in the quarter ending March 31, 2026, with 50.82% growth. This brings the company's revenue in the last twelve months to $3.93M, up 160.53% year-over-year. In the year 2025, Camp4 Therapeutics had annual revenue of $3.50M with 436.50% growth.
Revenue (ttm)
$3.93M
Revenue Growth
+160.53%
P/S Ratio
53.79
Revenue / Employee
$81,958
Employees
48
Market Cap
218.61M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 3.50M | 2.85M | 436.50% |
| Dec 31, 2024 | 652.00K | 302.00K | 86.29% |
| Dec 31, 2023 | 350.00K | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCAMP News
- 7 days ago - Camp4 Therapeutics receives Australia TGA clearance for CMP-002 trial - TheFly
- 7 days ago - CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder - GlobeNewsWire
- 17 days ago - CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - X4 Pharmaceuticals appoints CAMP4 Therapeutics CFO Kelly Gold to board - TheFly
- 6 weeks ago - CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - Camp4 Therapeutics upgraded to Overweight from Neutral at JPMorgan - TheFly
- 7 weeks ago - Camp4 Therapeutics Transcript: AGM 2026 - Transcripts
- 7 weeks ago - Camp4 Therapeutics initiated with a Buy at Chardan - TheFly